Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting
Shuai Wang1,2,3, Lijie Zhao1,2,3, Xiao-Jing Shi1,2,3
1School of Pharmaceutical Sciences and Institute of Drug Discovery & Development , Zhengzhou University , Zhengzhou 450001 , China.
Abstract:
The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our in-house library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5- a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated.
Insights
Researchers developed novel triazolo[1,5- a]pyrimidine inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 selectively inhibits Cul3/1 neddylation, showing therapeutic potential for diseases linked to cullin-RING ubiquitin ligase dysfunction.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Cullin-RING ubiquitin ligases (CRLs) regulate ~20% of cellular protein degradation and are implicated in human diseases.
- Targeting CRLs is an emerging therapeutic strategy for various diseases.
Purpose of the Study:
- To discover and optimize novel inhibitors targeting the DCN1-UBC12 interaction.
- To evaluate the therapeutic potential of these inhibitors for diseases involving CRL dysfunction.
Main Methods:
- Hit compound discovery from an in-house library.
- Structure-based optimization of triazolo[1,5- a]pyrimidine derivatives.
- Biochemical assays to determine inhibitory activity (IC50) and selectivity.
- Cellular assays to assess target engagement and downstream effects.
Main Results:
- Identified WS-383, a potent and reversible inhibitor of the DCN1-UBC12 interaction (IC50 = 11 nM).
- WS-383 demonstrated selectivity over other kinases and inhibited Cul3/1 neddylation selectively.
- Compound showed cellular target engagement with DCN1 and induced accumulation of p21, p27, and NRF2.
Conclusions:
- Targeting the DCN1-UBC12 interaction is a viable strategy for selective Cul3/1 neddylation inhibition.
- WS-383 and similar compounds hold therapeutic potential for diseases associated with dysregulated Cul3/1 activity.
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Protein-protein Interfaces
Protein and Protein Structure
A protein's shape is critical to its function. For example, an enzyme...
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Activation and Inactivation of G Proteins


